Veterinary Medicines Directorate

United Kingdom
Veterinary Medicines Directorate
Woodham Lane
New Haw
Addlestone
Surrey KT15 3LS

NATIONAL PROCEDURE

PUBLICLY AVAILABLE ASSESSMENT REPORT FOR A VETERINARY MEDICINAL PRODUCT

Tramalgesic 50 mg Tablets for Dogs

Date Created: February 2022

MODULE 1

PRODUCT SUMMARY

Name, strength and pharmaceutical form	Tramalgesic 50 mg Tablets for Dogs, Tablet
Applicant	Drug Development Company Limited, 2nd Floor Godfree Court, Apex Yard, 29 Long Lane, London, SE1 4PL
Active substance	Tramadol hydrochloride
ATC Vetcode	QN02AX02
Target species	Dogs
Indication for use	For the reduction of acute and chronic mild soft tissue musculoskeletal pain

MODULE 2

The Summary of Product Characteristics (SPC) for this product is available on the Product Information Database of the Veterinary Medicines Directorate.

(www.gov.uk/check-animal-medicine-licensed)

MODULE 3

PUBLIC ASSESSMENT REPORT

Legal basis of original application	Generic application in accordance with Article 13(1) of Directive 2001/82/EC as amended.
Date of conclusion of the procedure	23rd February 2022

I. SCIENTIFIC OVERVIEW

This was an application for a generic product, Tramalgesic 50 mg Tablets for Dogs. The product has been developed as a generic of the product Altadol 50 mg compresse solubilii per cani that has been authorised in Italy since 16 June 2005. This application is for an authorisation in the UK only. The product contains 50 mg tramadol hydrochloride (equivalent to 43.9 mg tramadol base) per tablet. The product is indicated for use in dogs for the reduction of acute and chronic mild soft tissue and muscoskeletal pain.

The product is produced and controlled using validated methods and tests which ensure the consistency of the product released on the market. It has been shown that the product can be safely used in the target species, any reactions observed are indicated in the SPC.[1] The product is safe for the user, and for the environment, when used as recommended. Suitable warnings and precautions are indicated in the SPC. The efficacy [2] of the product was demonstrated according to the claims made in the SPC. The overall benefit/risk analysis is in favour of granting a marketing authorisation.

II. QUALITATIVE AND QUANTITATIVE PARTICULARS OF THE CONSTIUENTS

II.A. Composition

The product contains tramadol hydrocholoride 50 mg equivalent to 43.9 mg tramadol base and the excipients are cellulose microcrystalline, maize starch, saccharin sodium, artificial beef flavour, silica colloidal anhydrous and magnesium stearate.

The container/closure system consists of induction sealed polypropylene containers with child-resistant polypropylene closures. The particulars of the containers and controls performed are provided and conform to the regulation.

[1] SPC – Summary of product Characteristics.
[2] Efficacy – The production of a desired or intended result.

The choice of the formulation and the absence of preservative are justified.

The product is an established pharmaceutical form and its development is adequately described in accordance with the relevant European guidelines.

II.B. Description of the Manufacturing Method

The product is manufactured fully in accordance with the principles of good manufacturing practice from a licensed manufacturing site. The manufacturing method consists of preparing the starch paste then granulation of it before mixing. The product is then dried, milled and blended. Lastly, it is lubricated and compressed.

The product is manufactured using conventional manufacturing techniques. Process validation for full-scale batches will be performed post-authorisation.

II.C. Control of Starting Materials

The active substance is tramadol hydrochloride, an established active substance described in the European Pharmacopoeia (Ph. Eur). The active substance is manufactured in accordance with the principles of good manufacturing practice.

The active substance specification is considered adequate to control the quality of the material. Batch analytical data demonstrating compliance with this specification have been provided.

The active substance is supplied against a valid CEP.

All the excipients, except for the flavouring component, comply with their respective Ph. Eur. monographs. The flavouring component complies with Directive 88/388/EEC. Suitable specifications were provided for the packaging materials.

II.C.4. Substances of Biological Origin

Porcine liver is used as a basis for the Artificial Beef Flavour.
Scientific data and/or certificates of suitability issued by the EDQM have been provided and compliance with the Note for Guidance on Minimising the Risk of Transmitting Animal Spongiform Encephalopathy Agents via Human and Veterinary Medicinal Products has been satisfactorily demonstrated.

II.D. Control Tests Carried Out at Intermediate Stages of the Manufacturing Process

Not applicable.

II.E. Control Tests on the Finished Product

The finished product specification controls the relevant parameters for the pharmaceutical form. The tests in the specification, and their limits, have been justified and are considered appropriate to adequately control the quality of the product. Satisfactory validation data for the analytical methods have been provided. Batch analytical data from the proposed production sites have been provided demonstrating compliance with the specification. Control tests on the finished product are those for: appearance, identification, average weight, diameter, thickness, average tablet hardness, friability, disintegration, dissolution, water content, uniformity of dosage units, assay, related substances and microbiological quality.

II.F. Stability

Stability data on the active substance have been provided in accordance with applicable European guidelines, demonstrating the stability of the active substance when stored under the approved conditions. The re-test period is 5 years.

Stability data on the finished product have been provided in accordance with applicable European guidelines, demonstrating the stability of the product throughout its shelf life when stored under the approved conditions.

G. Other Information

Shelf life of the veterinary medicinal product as packaged for sale: 1 year
Do not store above 25°C.
Store in the original container in order to protect from moisture.
Half or quarter tablets should be replaced back into the original container and should be given at the next administration.

III. SAFETY AND RESIDUES DOCUMENTATION (PHARMACO-TOXICOLOGICAL)

The application for a national Marketing Authorisation has been made in accordance with Article 13(1) of Directive 2001/82/EC, as amended. The reference product is Altadol 50 mg compresse solubilii per cani, which has been authorised since 2005 in Italy. The reference product is not authorised in the UK. It is stated that the product has the same qualitative and quantitative composition in terms of the active substances as the reference product, and has the same pharmaceutical form. A biowaiver has been accepted.

III.A Safety Documentation

Pharmacological Studies

As this is a generic application no data were required.

Toxicological Studies

As this is a generic application no data were required.

User Safety

A user risk assessment was provided in compliance with the relevant guideline. The applicant has provided a thorough URA, written in accordance with current guidance. It identified the routes of exposure as dermal contact during dividing and administering the tablets by both the professional and non-professional user and accidental ingestion by a child.

For dermal exposure, no quantitative URA was performed. The applicant considered that contact will lead to negligible exposure and can be mitigated for by normal hygiene measures such as hand washing. Given that minimal dust is expected and this is a compressed tablet, this assumption was acceptable and the 'wash hands after use' risk mitigation measure was agreed. This is in line with other recently authorised products containing tramadol and in line with the human equivalent product.

For accidental ingestion, there is a scenario that a child could access the product during the pre-administration phase, i.e. during storage, where there is a risk that all 56 or 200 tablets could be accessed. To mitigate for this scenario, the product is packaged in child-resistant containers and proposed to be kept out of the sight and reach of children. The applicant should be aware that the reference product is packaged in blisters and that blisters are the preferred choice of packaging for a tablet, however, as the packaging has been demonstrated to be child-resistant, this can be accepted at the current time/for this procedure, with further information that the container should be securely closed after each withdrawal of tablets.

The applicant has also indicated that if smaller numbers of tablets are required for a patient, these should be provided in child-resistant containers for continued risk mitigation.

Warnings and precautions as listed on the product literature are adequate to ensure safety to users of the product. Therefore the following applicant's user recommendations are appropriate:,

- Accidental ingestion of this product may be harmful, especially to children. Tramadol may cause sedation, nausea and dizziness.
- If smaller quantities of tablets are dispensed from the pack, they must be supplied in a container with a child-resistant closure.
- To avoid accidental ingestion by a child, the cap of the container must be securely engaged at all times. Tablets to be administered must not be left unattended and unused part tablets should be returned to the container.

- In case of accidental ingestion, particularly by children, seek medical advice immediately and show the package leaflet or the label to the physician. Do not drive as sedation may occur.
- People with known hypersensitivity to tramadol should avoid contact with the veterinary medicinal product.
- Wash hands after use.

Environmental Safety

The Environmental Risk Assessment (ERA) was carried out in accordance with VICH and CVMP guidelines.

Phase I:
The product will only be used in non-food animals and as a result environmental exposure will be low. A Phase II ERA was not required.

Non-food producing species only.

IV. CLINICAL DOCUMENTATION

IV.I. Pre-Clinical Studies

As this is a generic application no data were required.

Tolerance in the Target Species

Tolerance studies were not required because bioequivalence with the reference product has been established.

Resistance

No resistance studies were required based on the nature of the application.

IV.II. Clinical Documentation

No clinical studies were required based on the nature of the application.

V OVERALL CONCLUSION AND BENEFIT– RISK ASSESSMENT

The data submitted in the dossier demonstrate that the benefit/risk profile of the product is favourable.

MODULE 4

POST- AUTHORISATION ASSESSMENTS

The SPC and package leaflet may be updated to include new information on the quality, safety and efficacy of the veterinary medicinal product. The current SPC is available on the Product Information Database of the Veterinary Medicines Directorate website.

(www.gov.uk/check-animal-medicine-licensed)

The post-authorisation assessment (PAA) contains information on significant changes which have been made after the original procedure which are important for the quality, safety or efficacy of the product.

The PAA for this product is available on the Product Information Database of the Veterinary Medicines Directorate website.

(www.gov.uk/check-animal-medicine-licensed)